Each month the FormsNet3 team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.

March 2024 (released March 22nd, 2024)

Form_Revision Question Type of Change Current New Rationale for Change
F4006 r6 Q33 Validation (Add) Q33 (Specify start date) must be between date of product infusion and date of product infusion +2 days. Q33 (Specify start date) must be greater than or equal to event date Allows for a broader date range to be reported
F2003 r1 Q3-5 Validation (Modify) If and only if Q2 = Gene Therapy product ID, then Q3 must be answered.
If and only if Q2 = Batch number, then Q4 must be answered.
If and only if Q2 = Lot number, then Q5 must be answered.
If Q2 contains Gene Therapy product ID, then Q3 must be answered.
If Q2 contains Batch number, then Q4 must be answered.
If Q2 contains Lot number, then Q5 must be answered.
Fixing previously incorrect validations to work as initially intended

February 2024 (released February 23rd, 2024)

Form_Revision Question Type of Change Current New Rationale for Change
F2402 r7 Q415 Validation (Modify) If Q413 is multiple myeloma then Q415 may contain any combination of heavy and light chain options If and only if Q413 is answered as multiple myeloma then Q415 must contain only heavy chain OR only light chain options. Will receive error if both heavy and light chain options are reported together Prevent contradicting information from being reported
F2100 r9 Q121 and 191 Modify (Floating Text) Brand names listed next to drug options Brand names no longer listed next to drug options. Only generic drug names are listed on form Eliminate reporting confusion

January 2024 (released January 26th, 2024)

Form_Revision Question Type of Change Current New Rationale for Change
F2402 r7 Q469-501 Validation (Modify) Q469-501 are required for Thalassemia Q469-501 will still be required for Thalassemia. Q469-474, 477-494 & 499-501 will be answered for Sickle Cell Disease These questions will now be required for both Thalassemia and Sickle Cell Disease (previously only required for Thalassemia)
F2030 r3 Q28-29, 38-40, 41-46 Validation (Modify) If Q27 = yes, then Q28 must be answered.
Q38 & Q41 must be answered
Q28, 38 & 41 no longer need to be answered Because these questions are now answered on F2402 (see above revision), they will be disabled on F2030 to avoid duplicate reporting
F2402 r7 Q93-101, 169-177 Validation (Modify) MRD questions are disabled MRD questions are enabled
AML: Q93-95 & 99-101
ALL: Q169-171 & 175-177
For AML and ALL, these MRD questions are now required to be answered

December 2023 (released December 8th, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2100 r9 Q209-211 Validation (Add) Questions required only for recipients with acute or chronic GVHD Questions required for all ALLO recipients regardless of GVHD status Information required for all ALLO patients
F2100 r9 Q348-349 Validation (Modify) Active questions Inactive questions No longer collecting data
Note: If questions were previously answered, data will be removed from form
F2116 r5 Q110-141 Validation (Add) If Q4 = yes, must answer Q110-141 Will not need to re-answer Q110-141 Burden reduction
F2116 r5 Q228 and Q230 Validation (Modify) Questions must always be answered If Q1 = AMYL or MRGS OR Q2 contains AMYL or MGRS, then Q228 and 230 must be answered Only captured at baseline for AMYL or MGRS and should only be captured for same diseases at follow-up
Note: If questions were previously answered for data that is not AMYL or MGRS, data will be removed from form
F2014/2114, F2016, F2028/2128, F2057/2157 Validation (Modify) Karyotype ISCN string field does not exist Karyotype ISCN string field added Expanding functionality

November 2023 (released November 17th, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2100 r9 Q317 Validation (Modify) If cardiac impairment/disorder = arrhythmia or pericarditis, then Q317 must be answered If cardiac impairment/disorder = arrhythmia, pericarditis or cardiomyopathy, then Q317 must be answered Cardiomyopathy has been added as a cardiac impairment/disorder that, when reported, makes Q317 required
F2402 r7 Q92 & Q168 Validation (Modify) If disease status = 1CR, 2CR, or GE3CR, then number of cycles of induction therapy required to achieve 1st CR must be answered If disease status = 1CR, then number of cycles of induction therapy required to achieve 1st CR must be answered A disease status that is anything but 1CR implies the disease is more aggressive. Thus, only patients in 1CR should have this question answered
F2116 r5 Q30 Validation (Modify) If Q1 = amyloidosis, MGRS or other PCD OR Q2 contains amyloidosis or MGRS, then Q30 must be answered
If Q4 or Q7 = no, then Q30 must be answered
If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q30 must be answered Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users
F2116 r5 Q32 Validation (Modify) If Q1 = amyloidosis, MGRS, other PCD OR Q2 = amyloidosis or MGRS, then Q32 must be answered
If Q4 or Q7 = no, then Q32 must be answered
If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q32 must be answered ​Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users
F2400 r10 Q61 Validation (Modify) If Q45 contains single cord blood unit or Q44 = allogeneic, unrelated and Q55 is not answered, then Q61 must be answered If Q45 contains single cord blood unit and Q53 = no OR Q44 = allogeneic, unrelated and Q45 contains any (BM, PBSC, Other) and Q55 is not answered, then Q61 must be answered Cord blood units facilitated through NMDP are not required to answer the Cord Blood Bank, this question is now optional. Note: optional fields will appear enabled, but there will not be a validation error if it is left blank

October 2023 (released October 27, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2402 r6 Q18, 45, 72, 110,
129, 148, 213, 250,
301, 358, 436
Validation (Add) ISCN validations do not exist ISCN validations added Support AGNIS centers using 2402r6

September 2023 (released September 22, 2023)

No updates to communicate.

August 2023 (released August 25, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2100 r7-8
F2149 r1
F2900 r4-5
F4100 r5-9
Events and Actions If COVID-19 (SARS-CoV-2) infection is reported F2149 comes due F2149 will not come due Data no longer being collected except for BMT CTN 2101 study
F2149 r1 Events and Actions On-demand capability enabled On-demand capability removed, CIBMTR will add form manually Data no longer being collected except for BMT CTN 2101 study

July 2023 (released July 28, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2000 r6 Q115 Validation (Modify) If country of primary residence is EQUAL to any (AS, GU, MP, PR, US, UM, VI) then household income must be answered Household income question will be disabled for all To coincide with cell therapy form updates and reduce reporting burden
F4000, F4100, F4003, F4006, F4101 Option group (add and modify) Afamitresgene autoleucel added to cell therapy product list and Orvacabtagene autoleucel removed from cell therapy product list Changes in availability/production of cell therapy products
F2400 r10 Q19 Option group (add) Four COG studies added to the dropdown list. These include: COG AALL1732, COG AAML1831, COG APAL2020SC (PedAL) and COG ASCT2031 Updating list to include additional studies
F2400 r10 and F4000 r10 Q17 (F2400) and Q9 (F4000) Option group (modify) Study sponsor list includes “RCI BMT RCI BMT” has been changed to “CIBMTR CRO Services” Change in sponsor name​
F2400 r10 and 2003 r1 Q79 (2400) and Q1 (2003) Option group (add) Only option for gene therapy product name is “other name” New options for gene therapy products added. Product options include: Betibeglogene autotemcel (Zynteglo®), Elivaldogene autotemcel (Skysona®), Exagamglogene autotemcel and Other name (specify) Updating list to add gene therapy product names

June 2023 (released June 23, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2010, F2011, F2014, F2016, F2018, F2057 CT is reported as a prior line of therapy CT is no longer reported as prior line of therapy Consistency between HCT and CT reporting

May 2023 (released May 19, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2450r7 / F2100r4-8 Q16 (F2450) / Q18 (F2100) Validation (Add) “Not Applicable” available as answer option “Not Applicable” will NOT be allowed to be reported for 6M, 1Y, and 2Y reporting periods Consistency with ANC data capture update in April
F4100r8/9 Q180 and 187 (r8) / Q153 and 160 (r9) Validation (Modify) If current treatment path is equal to 2, questions must be answered Disabled for combined follow-up when 2nd event is HCT Burden reduction
F2450r7 / 2011r8 Q67 (F2450) / Q65 (F2100) Answer option reads “PCR (includes quantitative, real time, and fluorescent multiplex)” Option PCR changed to “Single nucleotide polymorphisms (SNPs) (includes quantitative PCR, real-time PCR, sequencing, other)” Updated for more inclusive data capture

April 2023 (released April 21, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2400 r10 Q135 Validation (Add) No option available to report “none” “None” available as answer option Allows “None” as answer without requiring override error code
F2400 r10 Q21 Validation (Modify) If recipient is participating in a clinical trial AND Study Sponsor = Other Sponsor OR Study ID = BMT CTN 1903, then NCT ID must be answered NCT ID required for all clinical trials All clinical trials will report NCT ID.
Exception: RCI BMT studies with no NCT ID – reporting NCT ID will be optional in this case

February 2023 (released February 24, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2600 r5 / r6 Validation (Modify) If HCT = allo unrelated AND product type is BM or PBSC, then GRID must be answered If HCT = allo unrelated AND product type is BM or PBSC OR HCT = allo related and NMDP product, then GRID must be answered Include allo related NMDP product infusions

January 2023 (released January 27, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2100 r8 Q136 Validation (Modify) Disabled for the 100 day visit Enabled for both acute and chronic GVHD Allows capture of GVHD that persists across infusions

December 2022 (released December 9, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2013 r3 Q3 Validation (Modify) If subsequent transplant or cell therapy, then Q3 is disabled Q3 must be answered for every transplant and cell therapy (regardless if subsequent or first) Provides disease status at latest assessment
F2900 r5 Events & Actions If primary cause of death = COVID-19 OR contributing cause of death contains COVID-19, then a F2149 comes due As of November 2022, F2149 will not come due for TED track (except those enrolled in CTN 2101 study) F2149 is no longer collected for TED track
F2000 r6 Q80 Validation (Modify) No decimal place available when entering dosing weight One decimal place available when entering dosing weight Exact dosing weight necessary to capture data accurately, especially in pediatric patients
Last modified: Mar 22, 2024